Cinocap® (Cream, Aerosol) Instructions for Use
ATC Code
D11AX12 (Zinc pyrithione)
Active Substance
Pyrithione zinc (Rec.INN registered by WHO)
Clinical-Pharmacological Group
A drug with antiproliferative, antibacterial, and antifungal action for topical use
Pharmacotherapeutic Group
Other drugs used in dermatology
Pharmacological Action
Dermatoprotective drug. Pyrithione zinc possesses anti-inflammatory, antibacterial, and antifungal activity.
The antibacterial activity of zinc pyrithione is manifested against a number of gram-positive and gram-negative bacteria: Streptococcus spp., Staphylococcus spp., Escherichia coli, Pseudomonas aeruginosa, Proteus spp.
Pyrithione zinc reduces the intracellular level of ATP, promotes depolarization of cell membranes, causing the death of fungi and bacteria.
Antifungal activity is especially pronounced against Pityrosporum ovale and Pityrosporum orbiculare, which cause inflammation and excessive flaking in dandruff, seborrheic dermatitis, psoriasis, and other skin diseases.
The mechanism of anti-inflammatory action has not been studied.
Pharmacokinetics
Systemic absorption is insignificant. The drug is detected in the blood in trace amounts.
Indications
- Psoriasis;
- Atopic dermatitis (eczema, neurodermatitis);
- Seborrheic dermatitis.
ICD codes
| ICD-10 code | Indication |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L21 | Seborrheic dermatitis |
| L30.0 | Nummular eczema |
| L40 | Psoriasis |
| ICD-11 code | Indication |
| 9A06.70 | Atopic eczema of the eyelids |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA81.Z | Seborrheic dermatitis, unspecified |
| EA82 | Nummular dermatitis |
| EA85.20 | Atopic hand eczema |
| EA90.Z | Psoriasis, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Cream
The drug is intended for external use in adults and children aged 1 year and older.
The cream is applied in a thin layer to the affected areas 2-3 times/day.
The duration of treatment for psoriasis is 1-1.5 months, repeated courses are conducted upon the appearance of signs of exacerbation; for atopic dermatitis – 3-4 weeks; for seborrheic dermatitis – 2 weeks.
Aerosol
The drug is intended for external use in adults and children aged 1 year and older.
Shake the can before use. Spray the drug onto the affected area of the skin from a distance of about 15 cm for 3 seconds, covering an area equal to the size of a palm (which is equivalent to the consumption of 1 ml of the drug). The affected area is treated 2-3 times/day until a clinical effect is achieved. An additional nozzle is included for applying the drug to the scalp.
It is recommended to continue using the drug for 1 week after the symptoms disappear.
The duration of treatment for psoriasis is 1-1.5 months, repeated courses are conducted upon the appearance of signs of exacerbation; for atopic dermatitis – 3-4 weeks; for seborrheic dermatitis – 2 weeks.
Adverse Reactions
Possible allergic reactions.
The drug is usually well tolerated.
Contraindications
- Children under 1 year of age;
- Hypersensitivity to the components of the drug.
Use in Pregnancy and Lactation
Safety data for the use of the drug Cinocap® during pregnancy and lactation (breastfeeding) are not provided.
Pediatric Use
Contraindicated: children under 1 year of age.
Special Precautions
When spraying, the can should be held vertically.
Overdose
To date, no cases of zinc pyrithione overdose have been reported.
Drug Interactions
No clinically significant interaction of zinc pyrithione with other drugs has been identified.
Storage Conditions
The drug should be stored out of the reach of children at a temperature from 4°C (39.2°F) to 30°C (86°F).
Shelf Life
The shelf life is 2 years.
Dispensing Status
The drug is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Cream for external use 0.2%: tubes 25 g or 50 g
Marketing Authorization Holder
Otisipharm, JSC (Russia)
Dosage Form
 |
Cinocap® | Cream for external use 0.2%: tubes 25 g or 50 g |
Dosage Form, Packaging, and Composition
Cream for external use 0.2% white or white with a yellowish tint, odorless or with a weak specific odor.
| 1 g | |
| Pyrithione zinc | 2 mg |
Excipients: macrogol cetostearyl ether, cetostearyl alcohol, liquid paraffin (vaseline oil), propylene glycol, dexpanthenol (D-panthenol), sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dodecahydrate, purified water.
25 g – aluminum tubes (1) – cardboard boxes.
50 g – aluminum tubes (1) – cardboard boxes.
External use aerosol 0.2%: 58 g can
Marketing Authorization Holder
Otisipharm, JSC (Russia)
Dosage Form
|
Cinocap® | External use aerosol 0.2%: 58 g can |
Dosage Form, Packaging, and Composition
Aerosol for external use 0.2% in the form of an oily liquid from white to light yellow in color with a specific odor.
| 1 g | |
| Pyrithione zinc | 2 mg |
Excipients: sodium lauryl sulfate, isopropyl myristate, colloidal silicon dioxide (aerosil), dexpanthenol (D-panthenol), polysorbate 80 (tween 80), ethanol (rectified ethyl alcohol), tetrafluoroethane (freon 134a).
58 g – aluminum aerosol cans (1) complete with a spray nozzle – cardboard boxes.
![Cinocap® [Cream, Aerosol] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Cinocap® [Cream, Aerosol] 2")